Skip to main content

Table 4 Adjusted odds ratios*

From: Analysis of the relationship between the HbA1c screening results and the development and worsening of diabetes among adults aged over 40 years: a 4-year follow-up study of 140,000 people in Japan – the Shizuoka study

 

Model 1

 

Model 2

 

Variables

Odds ratio (95% CI)

p-value

Odds ratio (95% CI)

p-value

HbA1c status

 Group A

Ref.

 

Ref.

 

 Group B

22.64 (14.66–34.99)

< 0.001

3.02 (0.84–10.97)

0.09

 Group C

90.83 (76.33–108.08)

< 0.001

0.54 (0.25–1.18)

0.12

 Group D

36.95 (33.10–41.26)

< 0.001

0.28 (0.12–0.61)

< 0.01

Number of health check-ups between April 2014 and March 2018

 0

Ref.

 

Ref.

 

 1

0.84 (0.66–1.08)

0.19

0.52 (0.20–1.38)

0.19

 2

0.99 (0.79–1.25)

0.94

0.45 (0.18–1.14)

0.09

 3

1.04 (0.84–1.29)

0.73

0.24 (0.09–0.61)

< 0.01

 4

0.88 (0.72–1.07)

0.20

0.19 (0.09–0.42)

< 0.001

Age, years

1.01 (1.00–1.01)

0.08

0.98 (0.95–1.01)

0.17

Sex

 Female

1.05 (0.92–1.20)

0.48

1.13 (0.63–2.05)

0.68

 Male

Ref.

 

Ref.

 

BMI

1.08 (1.07–1.10)

< 0.001

 

SBP, mmHg

1.01 (1.00–1.01)

< 0.001

 

DBP, mmHg

0.99 (0.98–0.99)

< 0.001

 

Triglyceride, mg/dL

1.00 (1.00–1.00)

< 0.01

  

HDL, mg/dL

0.99 (0.99–0.99)

< 0.001

1.02 (1.00–1.03)

0.06

GOT, IU/L

0.99 (0.99–1.00)

0.06

 

GPT, IU/L

1.01 (1.01–1.02)

< 0.001

 

γ-GTP, IU/L

1.00 (1.00–1.00)

< 0.001

 

Hemoglobin, g/dL

1.10 (1.05–1.14)

< 0.001

 

Uric acid, mg/dL

 

 

Serum creatinine, mg/dL

1.31 (0.99–1.71)

0.06

 

eGFR, mL/min

1.01 (1.00–1.01)

< 0.001

  

Urine glucose

 Negative

Ref.

 

Ref.

 

 Trace

1.19 (0.84–1.69)

0.33

3.18 (1.01–10.00)

< 0.05

 1+

1.69 (1.20–2.37)

< 0.01

1.27 (0.29–5.64)

0.75

 2+

2.47 (1.55–3.92)

< 0.001

4.72 (1.45–15.36)

< 0.05

 3+

2.39 (1.58–3.63)

< 0.001

2.65 (0.83–8.44)

0.10

Urine protein (n, %)

 Negative

Ref.

 

Ref.

 

 Trace

1.14 (0.97–1.33)

0.10

1.39 (0.60–3.22)

0.44

 1+

1.27 (1.02–1.57)

< 0.05

2.24 (0.92–5.47)

0.08

 2+

1.21 (0.82–1.80)

0.34

1.89 (0.42–8.49)

0.41

 3+

1.59 (0.85–2.98)

0.15

 

Anti-hypertensive drugs

1.32 (1.19–1.47)

< 0.001

 

Lipid-lowering drugs

1.37 (1.24–1.52)

< 0.001

0.37 (0.17–0.78)

< 0.01

Treatment history

 Cerebrovascular disease

1.19 (0.97–1.46)

0.09

 

Daily smoking

1.14 (0.98–1.33)

0.08

 
  1. * Diabetes treatment initiation versus non-initiation in all participants (Model 1) and injection drug use versus oral drug use in treatment initiation group (Model 2). CI, confidence interval; HbA1c, hemoglobin A1c; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; GOT, glutamate-oxaloacetate transaminase; GPT, glutamate-pyruvate transaminase; γ-GTP, gamma-glutamyl transpeptidase; eGFR, epidermal growth factor receptor. Participants were divided into 4 groups according to HbA1c levels: group A, those whose HbA1c levels were < 6.5% in 2012 and 2013; group B, those whose HbA1c levels > 6.5% in 2012 but < 6.5% in 2013; group C, those whose HbA1c levels were > 6.5% in 2012 and 2013; and group D, those whose HbA1c levels were < 6.5% in 2012 and > 6.5% in 2013